GEORGE MASON UNIVERSITY

NOVEL PEPTIDE INHIBITOR

GMU-15-013

BREAKING THE CYCLE OF JOINT DAMAGE, RESTORING MOBILITY FOR LIFE

Mason's innovative solution addresses Post-Traumatic Osteoarthritis (PTOA) by disrupting the inflammatory cycle that drives joint degeneration following trauma. This groundbreaking therapy utilizes a novel peptide inhibitor, Arg286p, which targets specific inflammatory pathways. Unlike conventional treatments, Arg286p effectively halts the progression of joint damage at its source, offering a promising approach for service members and athletes alike.

Key Benefits

- **Targeted Inhibition:** Directly blocks both IL-1 and IL-33 inflammatory pathways, preventing further joint tissue damage
- **Advanced Protein Mapping:** Developed through Mason's proprietary protein painting technology to pinpoint precise protein interaction sites
- **Enhanced Efficacy:** Outperforms existing anti-inflammatory treatments by addressing both immune and non-immune cells in the joint
- **Potential for Immediate Intervention:** Designed for intra-articular injection, enabling rapid deployment following injury or during reconstructive surgery
- **Optimized for Stability:** Incorporates modifications for increased stability, specificity, and binding affinity, making it highly effective and durable



For More Information contact:
George Mason University, Office of Technology Transfer
703-993-8933 ott@gmu.edu https://ott.gmu.edu/